Merck veteran Perlmutter-led Eikon ?Therapeutics valued at $860 million in Nasdaq debut [Yahoo! Finance Canada]
Merck & Company, Inc. (new) (MRK)
Last merck & company, inc. (new) earnings: 4/28 06:45 am
Check Earnings Report
US:NYSE Investor Relations:
investors.merck.com/home/default.aspx
Company Research
Source: Yahoo! Finance Canada
Feb 5 (Reuters) - Drug developer Eikon Therapeutics, headed by Merck veteran Roger Perlmutter, was valued at about $860.3 ?million after its shares opened 5.3% below their offer price in ?their Nasdaq debut on Thursday. The Millbrae, California-based company's shares opened at $17.05 apiece, compared with the $18 offer ?price. Eikon sold roughly 21.2 million shares in an upsized IPO at the top end of its marketed range of $16 to $18 to raise $381.2 million. Eikon's debut comes amid a busy start for biotech IPOs this year following a subdued 2025, when regulatory ?changes at U.S. health agencies ?and federal funding cuts dissuaded many drug developers from going pubic. Cancer drug developer Aktis Oncology went public in New York ?last month, while hair-restoration drug developer Veradermics debuted on Wednesday. Drug developers SpyGlass Pharma and AgomAb Therapeutics are poised to go public in New York on Friday. While the IPO market ?has started 2026 on a steady footing, inve
Show less
Read more
Impact Snapshot
Event Time:
MRK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MRK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MRK alerts
High impacting Merck & Company, Inc. (new) news events
Weekly update
A roundup of the hottest topics
MRK
News
- Merck Announces Health Canada Approval of ENFLONSIA® for the prevention of RSV in newborns and infants [Globe and Mail, The (Toronto, Canada)]Globe and Mail, The
- Perlmutter-backed Eikon Therapeutics raises $381.2 million in IPO [Yahoo! Finance]Yahoo! Finance
- Jim Cramer on Merck & Co.: “This Is One of My Favorite Pharmaceutical Stocks” [Yahoo! Finance]Yahoo! Finance
- Moderna CEO hails breakthrough mRNA cancer vaccine that halves melanoma recurrence risk with Keytruda [FOX Business Network]FOX Business Network
- Where is Merck & Co. (MRK) Headed According to Wall Street? [Yahoo! Finance]Yahoo! Finance
MRK
Earnings
- 2/3/26 - Beat
MRK
Sec Filings
- 2/4/26 - Form 144
- 2/4/26 - Form 144
- 2/4/26 - Form 144
- MRK's page on the SEC website